Icahn blasts Amylin over spurned $3.5bn BMS bid
This article was originally published in Scrip
Executive Summary
Investor and shareholder activist Carl Icahn has lambasted the Amylin Pharmaceuticals board of directors for reportedly turning down a $22-per-share acquisition offer from Bristol-Myers Squibb in a 4 April letter to the San Diego biotechnology company.